Baillie Gifford & Co (AEHR) discloses passive 4.3% ownership in AEHR Test Systems
Filing Impact
Filing Sentiment
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary
Baillie Gifford & Co has reported a passive stake in AEHR Test Systems’ common stock below the 5% threshold. The firm beneficially owns 1,290,734 shares, representing 4.3% of the class, with sole voting and dispositive power over all of these shares.
Baillie Gifford & Co, an investment adviser based in Scotland, states that the AEHR shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the company or participating in any control-related transactions.
Positive
- None.
Negative
- None.
FAQ
What stake does Baillie Gifford & Co hold in AEHR Test Systems (AEHR)?
Baillie Gifford & Co beneficially owns 1,290,734 AEHR Test Systems common shares, representing 4.3% of the outstanding class. The firm reports sole voting and dispositive power over all these shares as of the event date disclosed.
Is Baillie Gifford & Co’s AEHR (AEHR) position passive or activist?
Baillie Gifford & Co characterizes its AEHR holdings as passive. It certifies the shares were acquired and are held in the ordinary course of business and not for changing or influencing control or participating in control-related transactions.
Why did Baillie Gifford & Co file an amended Schedule 13G/A for AEHR?
The amended Schedule 13G/A updates Baillie Gifford & Co’s beneficial ownership disclosure in AEHR Test Systems. It now reports 1,290,734 shares, or 4.3% of the class, which reflects ownership of 5 percent or less of the company’s common stock.
What does AEHR’s Schedule 13G/A say about Baillie Gifford & Co’s regulatory status?
Baillie Gifford & Co identifies itself as an investment adviser and a non-U.S. institution subject to a foreign regulatory scheme it says is substantially comparable to the U.S. equivalent. It undertakes to furnish additional information to Commission staff upon request.